JPMorgan analyst Chris Schott raised the firm’s price target on Merck (MRK) to $135 from $125 and keeps an Overweight rating on the shares ahead of the earnings report on April 30. The firm expects no major surprises in the quarter and sees the focus of the story remaining on Merck’s pipeline. JPMorgan continues to see a favorable risk/return for the shares heading into the 2026 and 2027 data readouts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Best ETFs to Invest In, According to AI Analyst
- White House says imposing tariffs on patented pharmaceutical products
- Trump Trade: President says Iran war will still take weeks
- Adagene announces results from the latest data cut of muzastotug study
- Merck initiates Phase 2b/3 trial evaluating MK-8748